Kinnate Biopharma Inc.

Kinnate Biopharma Inc., a precision oncology company, focuses on the discovery, designing, and development of small molecule kinase inhibitors for treating genomically defined cancers in the United States. It develops KIN-3248, a fibroblast growth factor receptors (FGFR) inhibitor, for the treatment of patients with intrahepatic cholangiocarcinoma and urothelial carcinoma, and other solid tumors; and small molecule programs, including KIN-7136, a MEK inhibitor, as well as KIN-8741, an c-MET inhibitor with broad mutational coverage across a variety of solid tumors; and KIN-7324, a cyclin-dependent kinase 4 inhibitor. The company was incorporated in 2018 and is based in San Diego, California. Kinnate Biopharma Inc. operates as a subsidiary of XOMA Corporation.